Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year ...

PRAX-114 Phase 2/3 monotherapy MDD Aria Study topline results expected in June 2022

Related Keywords

Boston ,Massachusetts ,United States ,Melbourne ,Victoria ,Australia ,American ,Alyssa Wyant ,Karl Hansen ,Steven Petrou ,Megan Sniecinski ,Marcio Souza ,Linkedin ,Ian Stone Canale Communications ,Twitter ,Mental Health ,American Epilepsy Society ,Florey Institute Of Neuroscience ,Nasdaq ,Committee For Orphan Medicinal Products ,University Of Melbourne ,Praxis Precision Medicines Inc ,Head Of The Florey Department ,Movement Disorders ,Drug Administration ,Cerebral Therapeutics Inc ,Exchange Commission ,European Medicines Agency ,Precision Medicines ,Maria Study ,Acapella Study ,Business Highlights ,Upcoming Milestones ,Major Depressive Disorder ,Orphan Medicinal Products ,Orphan Drug Designation ,Rare Pediatric Disease ,Cerebral Therapeutics ,Short Lasting Unilateral Neuralgiform ,Trigeminal Neuralgia ,Florey Institute ,Florey Department ,Full Year ,Praxis Precision Medicines ,Private Securities Litigation Reform Act ,Annual Report ,Although Praxi ,Alex Kane Praxis Precision Medicines ,Post Traumatic Stress Disorder ,Epilepsy ,Ung Disease ,Coronavirus ,Infectious Diseases ,Earnings Reports ,Depression ,Drug Trials ,Financial Performance ,Earnings ,Earnings Conference Calls ,Medical Research ,Clinical Trials ,Product Testing ,Economy ,Ecessions And Depressions ,Iseases And Conditions ,Neurological Disorders ,Corporate News ,Products And Services ,New Products And Services ,New Product Development ,Health ,Iagnosis And Treatment ,Medication ,Business ,Ealth Care Industry ,Medical Biotechnology Industry ,